The interaction of genetic polymorphisms with lifestyle factors: Implications for the dietary prevention of prostate cancer

Nutrition and Cancer

Volumn 60, Issue 3, 2008, Pages 301-312

  Nelson, Eric C ^a   Rodriguez, Raymond L ^a   Dawson, Kevin ^a   Galvez, Alfredo F ^a   Evans, Christopher P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MANGANESE SUPEROXIDE DISMUTASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RIBONUCLEASE L; SULFOTRANSFERASE 1A1; VITAMIN D RECEPTOR; XRCC1 PROTEIN; XRCC3 PROTEIN;

CANCER PREVENTION; CARCINOGENESIS; DNA REPAIR; ENVIRONMENTAL CHANGE; GENETIC POLYMORPHISM; HUMAN; LIFESTYLE; NONHUMAN; PROSTATE CANCER; REVIEW;

DIET; FOOD HABITS; HUMANS; LIFE STYLE; MALE; NUTRITION PHYSIOLOGY; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 42649083661     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701745319     Document Type: Review

References (95)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.: Cancer statistics, 2006. CA Cancer J Clin 56, 106-130, 2006.
2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, et al.: SEER Cancer Statistics Review, 1975-2004. Accessed August 24, 2007, http://seer.cancer.gov.csr/1975 2004/.
3. Blair A: Cancer and the Environment-NCI, 2007, http:// www.cancer.gov/newscenter/benchmarks-vol14-issue3/page1. Accessed August 24, 2007.
4. Divisi D, Di Tommaso S, Salvemini S, Garramone M, and Crisci R: Diet and cancer. Acta Biomed 77, 118-123, 2006.
5. Gonzalez CA: Nutrition and cancer: the current epidemiological evidence. Br J Nutr 96(Suppl 1), S42-S45, 2006.
6. Giovannucci E: Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 135, 2030S-2031S, 2005.
7. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, and Willett WC: A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94, 391-398, 2002.
8. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, and Willett WC: A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 12, 1403-1409, 2003.
9. Fleshner NE and Kucuk O: Antioxidant dietary supplements: rationale and current status as chemopreventive agents for prostate cancer. Urology 57, 90-94, 2001.
10. Ripple MO, Henry WF, Rago RP, and Wilding G: Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89, 40-48, 1997.
11. Sun XY, Donald SP, and Phang JM: Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22, 1775-1780, 2001.
12. Hirschhorn JN, Lohmueller K, Byrne E, and Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 4, 45-61, 2002.
13. Kaput J and Rodriguez RL: Nutritional genomics: the next frontier in the postgenomic era. Physiol Genomics 16, 166-177, 2004.
14. Wispe JR, Clark JC, Burhans MS, Kropp KE, Korfhagen TR, et al.: Synthesis and processing of the precursor for human mangano-superoxide dismutase. Biochim Biophys Acta 994, 30-36, 1989.
15. Chance B, Sies H, and Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 59, 527-605, 1979.
16. Costello LC and Franklin RB: The intermediarymetabolism of the prostate: a key to understanding the pathogenesis and progression of prostate malignancy. Oncology 59, 269-282, 2000.
17. Li N, Oberley TD, Oberley LW, and Zhong W: Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype. Prostate 35, 221-233, 1998.
18. Li JJ, Oberley LW, St Clair DK, Ridnour LA, and Oberley TD: Phenotypic changes induced in human breast cancer cells by overexpression of manganese-containing superoxide dismutase. Oncogene 10, 1989-2000, 1995.
19. Church SL, Grant JW, Ridnour LA, Oberley LW, Swanson PE, et al.: Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc Natl Acad Sci U S A 90, 3113-3117, 1993.
20. Liu R, Oberley TD, and Oberley LW: Transfection and expression of Mn-SOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. Hum Gene Ther 8, 585-595, 1997.
21. Yan T, Oberley LW, Zhong W, and St Clair DK: Manganese-containing superoxide dismutase overexpression causes phenotypic reversion in SV40-transformed human lung fibroblasts. Cancer Res 56, 2864-2871, 1996.
22. Baker AM, Oberley LW, and Cohen MB: Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32, 229-233, 1997.
23. Rosenblum JS, Gilula NB, and Lerner RA: On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci U S A 93, 4471-4473, 1996.
24. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, et al.: The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13, 145-157, 2003.
25. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, et al.: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene: a predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 226, 561-565, 1996.
26. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, et al.: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. Cancer Res 59, 602-606, 1999.
27. Mitrunen K, Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, et al.: Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22, 827-829, 2001.
28. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, and Hunter DJ: Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13, 989-996, 2004.
29. Cai Q, Shu XO, Wen W, Cheng JR, Dai Q, et al.: Genetic polymorphism in the manganese superoxide dismutase gene, antioxidant intake, and breast cancer risk: results from the Shanghai Breast Cancer Study. Breast Cancer Res 6, R647-R655, 2004.
30. Hennekens CH and Eberlein K: A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 14, 165-168, 1985.
31. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, et al.: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65, 2498-2504, 2005.
32. Lindahl T and Wood RD: Quality control by DNA repair. Science 286, 1897-1905, 1999.
33. Dianov GL, Prasad R, Wilson SH, and Bohr VA: Role of DNA polymerase beta in the excision step of long patch mammalian base excision repair. J Biol Chem 274, 13741-13743, 1999.
34. Thompson LH and West MG: XRCC1 keeps DNA from getting stranded. Mutat Res 459, 1-18, 2000.
35. Vidal AE, Boiteux S, Hickson ID, and Radicella JP: XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 20, 6530-6539, 2001.
36. Tebbs RS, Flannery ML, Meneses JJ, Hartmann A, Tucker JD, et al.: Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. Dev Biol 208, 513-529, 1999.
37. Shen MR, Jones IM, and Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58, 604-608, 1998.
38. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-deMurcia J, et al.: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18, 3563-3571, 1998.
39. Goode EL, Ulrich CM, and Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11, 1513-1530, 2002.
40. Blazer DG III, Umbach DM, Bostick RM, and Taylor JA: Vitamin D receptor polymorphisms and prostate cancer. Mol Carcinog 27, 18-23, 2000.
41. van Gils CH, Bostick RM, Stern MC, and Taylor JA: Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev 11, 1279-1284, 2002.
42. Brenneman MA, Weiss AE, Nickoloff JA, and Chen DJ: XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res 459, 89-97, 2000.
43. Han S, Zhang HT, Wang Z, Xie Y, Tang R, et al.: DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur J Hum Genet 14, 1136-1144, 2006.
44. Ritchey JD, Huang WY, Chokkalingam AP, Gao YT, Deng J, et al.: Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 14, 1703-1709, 2005.
45. Soejima H, Zhao W, and Mukai T: Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 83, 429-437, 2005.
46. Han J, Tranah GJ, Hankinson SE, Samson LD, and Hunter DJ: Polymorphisms in O6-methylguanine DNA methyltransferase and breast cancer risk. Pharmacogenet Genomics 16, 469-474, 2006.
47. Glatt H, Engelke CE, Pabel U, Teubner W, Jones AL, et al.: Sulfotransferases: genetics and role in toxicology. Toxicol Lett 112-113, 341-348, 2000.
48. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, et al.:Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 159, 113-121, 1995.
49. Al-Buheissi SZ, Patel HR, Meinl W, Hewer A, Bryan RL, et al.: N-Acetyltransferase and sulfotransferase activity in human prostate: potential for carcinogen activation. Pharmacogenet Genomics 16, 391-399, 2006.
50. Chou HC, Lang NP, and Kadlubar FF: Metabolic activation of N-hydroxy arylamines and N-hydroxy heterocyclic amines by human sulfotransferase(s). Cancer Res 55, 525-529, 1995.
51. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, and Weinshilboum RM: Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239, 298-304, 1997.
52. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, et al.: Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 60, 6859-6863, 2000.
53. Wang Y, Spitz MR, Tsou AM, Zhang K, Makan N, et al.: Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. Lung Cancer 35, 137-142, 2002.
54. Bamber DE, Fryer AA, Strange RC, Elder JB, Deakin M, et al.: Phenol sulphotransferase SULT1A1*1 genotype is associated with reduced risk of colorectal cancer. Pharmacogenetics 11, 679-685, 2001.
55. Nowell S, Ratnasinghe DL, Ambrosone CB, Williams S, Teague-Ross T, et al.: Association of SULT1A1 phenotype and genotype with prostate cancer risk in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 13, 270-276, 2004.
56. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, et al.: Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 165, 171-177, 2001.
57. Hayes JD and Strange RC: Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res 22, 193-207, 1995.
58. McIlwain CC, Townsend DM, and Tew KD: Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25, 1639-1648, 2006.
59. Brooks JD, Weinstein M, Lin X, Sun Y, Pin SS, et al.: CGislandmethylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 7, 531-536, 1998.
60. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6, 733-743, 1997.
61. Kelada SN, Kardia SL, Walker AH, Wein AJ, Malkowicz SB, et al.: The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev 9, 1329-1334, 2000.
62. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, et al.: Glutathione S-transferase-mu (GSTM1) and -theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 8, 283-287, 1999.
63. Joseph MA, Moysich KB, Freudenheim JL, Shields PG, Bowman ED, et al.: Cruciferous vegetables, genetic polymorphisms in glutathione S-transferases M1 and T1, and prostate cancer risk. Nutr Cancer 50, 206-213, 2004.
64. Chouinard S, Pelletier G, Belanger A, and Barbier O: Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 30, 717-725, 2004.
65. MacLeod SL, Nowell S, Plaxco J, and Lang NP: An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer. Ann Surg Oncol 7, 777-782, 2000.
66. Hajdinjak T and Zagradisnik B: Prostate cancer and polymorphism D85Y in gene for dihydrotestosterone degrading enzyme UGT2B15: frequency of DD homozygotes increases with Gleason Score. Prostate 59, 436-439, 2004.
67. Park J, Chen L, Shade K, Lazarus P, Seigne J, et al.: Asp85tyr polymorphism in the udp-glucuronosyltransferase (UGT) 2B15 gene and the risk of prostate cancer. J Urol 171, 2484-2488, 2004.
68. Okugi H, Nakazato H, Matsui H, Ohtake N, Nakata S, et al.: Association of the polymorphisms of genes involved in androgenmetabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev 30, 262-268, 2006.
69. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, et al.: Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 15, 1473-1478, 2006.
70. Gsur A, Preyer M, Haidinger G, Schatzl G, Madersbacher S, et al.: A polymorphism in the UDP-Glucuronosyltransferase 2B15 gene (D85Y) is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11, 497-498, 2002.
71. Moon SJ, Fryer AA, and Strange RC: Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseases. Photochem Photobiol 81, 1252-1260, 2005.
72. Carlberg C: Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 164, 29-42, 2003.
73. Skowronski RJ, Peehl DM, and Feldman D: Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 136, 20-26, 1995.
74. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, et al.: Prediction of bone density from vitamin D receptor alleles. Nature 367, 284-287, 1994.
75. Colin EM, Weel AE, Uitterlinden AG, Buurman CJ, Birkenhager JC, et al.: Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) 52, 211-216, 2000.
76. Berndt SI, Dodson JL, Huang WY, and Nicodemus KK:Asystematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 175, 1613-1623, 2006.
77. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, et al.: A prospective study of plasma vitamin Dmetabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4, e103, 2007.
78. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, et al.: Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 7, 385-390, 1998.
79. Zadshir A, Tareen N, Pan D, Norris K, and Martins D: The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis 15, S5-97-101, 2005.
80. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, et al.: Germ-line mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30, 181-184, 2002.
81. Liu X, Schumacher FR, Plummer SJ, Jorgenson E, Casey G, et al.: Transfatty acid intake and increased risk of advanced prostate cancer: modification by RNASEL R462Q variant. Carcinogenesis 28, 1232-1236, 2007.
82. Mahmud S, Franco E, and Aprikian A: Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90, 93-99, 2004.
83. MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, et al.: Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295, 403-415, 2006.
84. Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, et al.: Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 120, 398-405, 2007.
85. deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, et al.: Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63, 259-263, 2004.
86. Hedelin M, Balter KA, Chang ET, Bellocco R, Klint A, et al.: Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. Prostate 66, 1512-1520, 2006.
87. Wolff TA and Wilson JE: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Am Fam Physician 74, 1759-1760, 2006.
88. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, et al.: Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 296, 1507-1517, 2006.
89. Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, and Adami HO: The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 249, 477-493, 2001.
90. Cook NR, Le IM, Manson JE, Buring JE, and Hennekens CH: Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 11, 617-626, 2000.
91. Ergun A, Lawrence CA, Kohanski MA, Brennan TA, and Collins JJ: A network biology approach to prostate cancer. Mol Syst Biol 3, 82, 2007.
92. Semmes OJ, Malik G, and Ward M: Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J Cell Biochem 98, 496-503, 2006.
93. Dupuis J and O'Donnell CJ: Interpreting results of large-scale genetic association studies: separating gold from fool's gold. JAMA 297, 529-531, 2007.
94. http://www.ncbi.nlm.nih.gov/SNP/. Accessed August 24, 2007.
95. Marotta F, Weksler M, Naito Y, Yoshida C, Yoshioka M, et al.: Nutraceutical supplementation: effect of a fermented papaya preparation on redox status and DNA damage in healthy elderly individuals and relationship with GSTM1 genotype: a randomized, placebo-controlled, cross-over study. Ann N Y Acad Sci 1067, 400-407, 2006.